-
1
-
-
0017624810
-
Effect of enoterohepatic circulation on the pharmacokinetics of spironolactone in man
-
Abshagen U., et al. Effect of enoterohepatic circulation on the pharmacokinetics of spironolactone in man. Naunyn-schmiedeberg's Arch. Pharmacol. 300:1977;281-287
-
(1977)
Naunyn-schmiedeberg's Arch. Pharmacol.
, vol.300
, pp. 281-287
-
-
Abshagen, U.1
-
2
-
-
0025675680
-
Remodeling of the right and left ventricles in experimental hypertension
-
Brilla C., Pick R., Tan L., Janicki J., Weber K. Remodeling of the right and left ventricles in experimental hypertension. Circ. Res. 67:1990;1355-1364
-
(1990)
Circ. Res.
, vol.67
, pp. 1355-1364
-
-
Brilla, C.1
Pick, R.2
Tan, L.3
Janicki, J.4
Weber, K.5
-
3
-
-
0345630502
-
Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion
-
Carpenter C., Davis J.O., Ayers C.R. Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion. J. Clin. Invest. 40:1961;26-2042
-
(1961)
J. Clin. Invest.
, vol.40
, pp. 26-2042
-
-
Carpenter, C.1
Davis, J.O.2
Ayers, C.R.3
-
4
-
-
0000084418
-
Steroidal aldosterone blockers. II
-
Cella J., Tweit R. Steroidal aldosterone blockers. II. J. Org. Chem. 24:1959;1109-1110
-
(1959)
J. Org. Chem.
, vol.24
, pp. 1109-1110
-
-
Cella, J.1
Tweit, R.2
-
6
-
-
0036893488
-
Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A and CYP3A5
-
Cook C.S., Berry L.M., Kim D.H., Burton E.G., Hribar J.D., Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A and CYP3A5. Drug Met. Dispos. 30:2002;1344-1351
-
(2002)
Drug Met. Dispos.
, vol.30
, pp. 1344-1351
-
-
Cook, C.S.1
Berry, L.M.2
Kim, D.H.3
Burton, E.G.4
Hribar, J.D.5
Zhang, L.6
-
7
-
-
84870858157
-
Antiandrogenic effect of spirolactones: Mechanism of action
-
Corval P., Michaud A., Menard J., Freifeld M., Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 104:1979;1194-1200
-
(1979)
Endocrinology
, vol.104
, pp. 1194-1200
-
-
Corval, P.1
Michaud, A.2
Menard, J.3
Freifeld, M.4
Mahoudeau, J.5
-
8
-
-
0018098679
-
SC-25152: A potent mineralocorticoid antagonist with reduced affinity for the 5α-dihydrotestosterone receptor of human and rat prostate
-
Cutler G.B., Pita J.C., Rifka S.M., Menard R.H., Sauer M.A., Loriaux D.L. SC-25152: A potent mineralocorticoid antagonist with reduced affinity for the 5α-dihydrotestosterone receptor of human and rat prostate. J. Clin. Endocrinal. Metab. 47:1978;171-175
-
(1978)
J. Clin. Endocrinal. Metab.
, vol.47
, pp. 171-175
-
-
Cutler, G.B.1
Pita, J.C.2
Rifka, S.M.3
Menard, R.H.4
Sauer, M.A.5
Loriaux, D.L.6
-
9
-
-
0018332936
-
SC-25152: A potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone
-
Cutler G.B., Sauer M.A., Loriaux D.L. SC-25152: A potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone. J. Pharmacol. Exp. Ther. 209:1979;144-146
-
(1979)
J. Pharmacol. Exp. Ther.
, vol.209
, pp. 144-146
-
-
Cutler, G.B.1
Sauer, M.A.2
Loriaux, D.L.3
-
10
-
-
0017225440
-
Mechanisms regulating renin release
-
Davis J.O., Freeman R.H. Mechanisms regulating renin release. Physiol. Rev. 56:1976;1-56
-
(1976)
Physiol. Rev.
, vol.56
, pp. 1-56
-
-
Davis, J.O.1
Freeman, R.H.2
-
11
-
-
0023117413
-
Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro
-
deGasparo M., Joss U., Ramjoue H.P., Whitebread S.E., Haenni H., Schenkel L., Kraehenbuehl C., Biollaz M., Grob J., Schmidlin J., Wieland P., Wehrli H.U. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharm. Exp. Ther. 240:1987;650-656
-
(1987)
J. Pharm. Exp. Ther.
, vol.240
, pp. 650-656
-
-
Degasparo, M.1
Joss, U.2
Ramjoue, H.P.3
Whitebread, S.E.4
Haenni, H.5
Schenkel, L.6
Kraehenbuehl, C.7
Biollaz, M.8
Grob, J.9
Schmidlin, J.10
Wieland, P.11
Wehrli, H.U.12
-
13
-
-
0035461193
-
Eplerenone: A selective aldosterone receptor antagonist (SARA)
-
Delyani J.A., Rocha R., Cook C.S., Tolbert D.S., Levin S., Roniker B., Workman D.L., Sing Y.-L., Whelihan B. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 19(3):2001b;185-200
-
(2001)
Cardiovasc. Drug Rev.
, vol.19
, Issue.3
, pp. 185-200
-
-
Delyani, J.A.1
Rocha, R.2
Cook, C.S.3
Tolbert, D.S.4
Levin, S.5
Roniker, B.6
Workman, D.L.7
Sing, Y.-L.8
Whelihan, B.9
-
14
-
-
0014341097
-
Mode of spirolactone action: Competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors
-
Fanestil D.D. Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochem. Pharmacol. 17:1968;2240-2242
-
(1968)
Biochem. Pharmacol.
, vol.17
, pp. 2240-2242
-
-
Fanestil, D.D.1
-
15
-
-
0037414091
-
Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients
-
Flack J.M., Oparil S., Pratt J.H., Roniker B., Garthwaite S., Kleiman J.H., Yang Y., Krause S.L., Workman D., Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J. Am. Coll. Cardiol. 41:2003;1148-1155
-
(2003)
J. Am. Coll. Cardiol.
, vol.41
, pp. 1148-1155
-
-
Flack, J.M.1
Oparil, S.2
Pratt, J.H.3
Roniker, B.4
Garthwaite, S.5
Kleiman, J.H.6
Yang, Y.7
Krause, S.L.8
Workman, D.9
Saunders, E.10
-
16
-
-
0016380105
-
Molecular modifications of anti-aldosterone compounds: Effects on affinity of spirolactones for renal aldosterone receptors
-
Funder J., Feldman D., Highland E., Edelman I. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem. Pharmacol. 23:1974;1493-1501
-
(1974)
Biochem. Pharmacol.
, vol.23
, pp. 1493-1501
-
-
Funder, J.1
Feldman, D.2
Highland, E.3
Edelman, I.4
-
17
-
-
0015912489
-
Adverse reactions to spironolactone: A report from the Boston Collaborative Drug Surveillance Program
-
Greenblatt D.J., Koch-Weser J. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. J. Am. Med. Assoc. 225:1973;40-43
-
(1973)
J. Am. Med. Assoc.
, vol.225
, pp. 40-43
-
-
Greenblatt, D.J.1
Koch-Weser, J.2
-
19
-
-
0014778519
-
Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder
-
Hutchinson J.H., Porter G.A. Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder. Res. Comm. Chem. Path. Pharm. 1(3):1970;363-369
-
(1970)
Res. Comm. Chem. Path. Pharm.
, vol.1
, Issue.3
, pp. 363-369
-
-
Hutchinson, J.H.1
Porter, G.A.2
-
20
-
-
0000167622
-
Action of new steroids blocking effects of aldosterone and desoxycorticosterone on salt
-
Kagawa C.M., et al. Action of new steroids blocking effects of aldosterone and desoxycorticosterone on salt. Science. 126:1957;1015-1016
-
(1957)
Science
, vol.126
, pp. 1015-1016
-
-
Kagawa, C.M.1
-
21
-
-
0018164753
-
Spironolactone: Disposition, metabolism, pharmacodynamics and bioavailability
-
Karim A. Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab. Rev. 8(1):1978;151-188
-
(1978)
Drug Metab. Rev.
, vol.8
, Issue.1
, pp. 151-188
-
-
Karim, A.1
-
22
-
-
0036330671
-
Addition of eplerenone to ACE inhibition or angiotensin blockade in hypertensive patients
-
Krum H., Nolly H., Workman D., He W., Roniker B., Krause S., Fakouhi K. Addition of eplerenone to ACE inhibition or angiotensin blockade in hypertensive patients. Hypertension. 40:2002;117-123
-
(2002)
Hypertension
, vol.40
, pp. 117-123
-
-
Krum, H.1
Nolly, H.2
Workman, D.3
He, W.4
Roniker, B.5
Krause, S.6
Fakouhi, K.7
-
24
-
-
0035320408
-
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist
-
McMahon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1:2001;190-196
-
(2001)
Curr. Opin. Pharmacol.
, vol.1
, pp. 190-196
-
-
McMahon, E.1
-
25
-
-
0023512031
-
The metabolism and biopharmaceutics of spironolactone in man
-
Overdiek H.W. The metabolism and biopharmaceutics of spironolactone in man. Drug Metab. Interact. 5:1987;273-302
-
(1987)
Drug Metab. Interact.
, vol.5
, pp. 273-302
-
-
Overdiek, H.W.1
-
26
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
-
Pitt B., Zannad F., Remme W., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Eng. J. Med. 341(10):1999;709-715
-
(1999)
N. Eng. J. Med.
, vol.341
, Issue.10
, pp. 709-715
-
-
Pitt, B.1
Zannad, F.2
Remme, W.3
Cody, R.4
Castaigne, A.5
Perez, A.6
Palensky, J.7
Wittes, J.8
-
27
-
-
0034916015
-
The EPHESUS Trial: Eplerenone in patients with heat failure due to systolic dysfunction complicating acute myocardial infarction
-
Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Neaton J., Rniker B., Hurley S., Burns D., Bittman R., Kleiman J. The EPHESUS Trial: eplerenone in patients with heat failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc. Drugs Ther. 15:2001;79-87
-
(2001)
Cardiovasc. Drugs Ther.
, vol.15
, pp. 79-87
-
-
Pitt, B.1
Williams, G.2
Remme, W.3
Martinez, F.4
Lopez-Sendon, J.5
Neaton, J.6
Rniker, B.7
Hurley, S.8
Burns, D.9
Bittman, R.10
Kleiman, J.11
-
28
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 348(14):2003;1309-1321
-
(2003)
N. Eng. J. Med.
, vol.348
, Issue.14
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
Neaton, J.4
Martinez, F.5
Roniker, B.6
Bittman, R.7
Hurley, S.8
Kleiman, J.9
Gatlin, M.10
-
29
-
-
0036838616
-
Aldosterone induces a vascular inflammatory phenotype in the rat heart
-
Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak N., Kekec B.K., Blomme E.A.G., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. 283:2002;H1802-H1810
-
(2002)
Am. J. Physiol.
, vol.283
, pp. 1802-H1810
-
-
Rocha, R.1
Rudolph, A.E.2
Frierdich, G.E.3
Nachowiak, N.4
Kekec, B.K.5
Blomme, E.A.G.6
McMahon, E.G.7
Delyani, J.A.8
-
30
-
-
0038819295
-
Protection by a steroid-spirolactone against certain types of cardiac necroses
-
Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc. Soc. Exp. Biol. Med. 104:1960;212-213
-
(1960)
Proc. Soc. Exp. Biol. Med.
, vol.104
, pp. 212-213
-
-
Selye, H.1
-
31
-
-
0011886496
-
Isolierung eines neuen kristallisierten hormons aus nebennieren mit besonderer hoher wirksamkeit auf den mineralstoff wechsel
-
Simpson S.A., Tait J.F., Wettstein A., Neher R., Von Euw V.J., Reichstein T. Isolierung eines neuen kristallisierten hormons aus nebennieren mit besonderer hoher wirksamkeit auf den mineralstoff wechsel. Experientia. 9:1953;33-38
-
(1953)
Experientia
, vol.9
, pp. 33-38
-
-
Simpson, S.A.1
Tait, J.F.2
Wettstein, A.3
Neher, R.4
Von Euw, V.J.5
Reichstein, T.6
-
32
-
-
84961040686
-
Prevention of adrenal-regeneration hypertension by an aldosterone-blocker
-
Sturtevant F.M. Prevention of adrenal-regeneration hypertension by an aldosterone-blocker. Endocrinology. 64:1959;299-300
-
(1959)
Endocrinology
, vol.64
, pp. 299-300
-
-
Sturtevant, F.M.1
-
33
-
-
0037016007
-
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
-
Suzuki G., Morita H., Mishima T., Sharov V.G., Todor A., Tanhehco E.J., Rudolph A.E., McMahon E.G., Goldstein S., Sabbah H.N. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 106:2002;2967-2972
-
(2002)
Circulation
, vol.106
, pp. 2967-2972
-
-
Suzuki, G.1
Morita, H.2
Mishima, T.3
Sharov, V.G.4
Todor, A.5
Tanhehco, E.J.6
Rudolph, A.E.7
McMahon, E.G.8
Goldstein, S.9
Sabbah, H.N.10
-
34
-
-
0141997157
-
Satefy, tolerability and pharmacokinetics of eplerenone, a selective aldosterone blocker
-
(abstract)
-
Tolbert D.S., Reid S.E., Roniker B. Satefy, tolerability and pharmacokinetics of eplerenone, a selective aldosterone blocker. Pharmacokinetics. 22(10):2002;1331. (abstract)
-
(2002)
Pharmacokinetics
, vol.22
, Issue.10
, pp. 1331
-
-
Tolbert, D.S.1
Reid, S.E.2
Roniker, B.3
-
35
-
-
0021889021
-
Assessment of the antimineralocorticoid effect of RU 28 318 in healthy men with induced exogenous and endogenous hyper-mineralocorticism
-
Ulmann A., Bertagna C., LeGo A., Husson J.M., Tache A., Sassano P., Menard J., Corvol P. Assessment of the antimineralocorticoid effect of RU 28 318 in healthy men with induced exogenous and endogenous hyper-mineralocorticism. Eur. J. Clin. Pharmacol. 28:1985;531-535
-
(1985)
Eur. J. Clin. Pharmacol.
, vol.28
, pp. 531-535
-
-
Ulmann, A.1
Bertagna, C.2
Lego, A.3
Husson, J.M.4
Tache, A.5
Sassano, P.6
Menard, J.7
Corvol, P.8
-
37
-
-
0035997359
-
Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension
-
Weinberger M., Roniker B., Krause S., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension. Am. J. Hypertens. 15(8):2002;709-716
-
(2002)
Am. J. Hypertens.
, vol.15
, Issue.8
, pp. 709-716
-
-
Weinberger, M.1
Roniker, B.2
Krause, S.3
Weiss, R.J.4
-
38
-
-
0038673178
-
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
-
White W.B., Duprez D., St. Hillaire R., Krause S., Roniker B., Juse-Hamilton J., Weber M.A. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 41:2003a;1021-1026
-
(2003)
Hypertension
, vol.41
, pp. 1021-1026
-
-
White, W.B.1
Duprez, D.2
St. Hillaire, R.3
Krause, S.4
Roniker, B.5
Juse-Hamilton, J.6
Weber, M.A.7
-
39
-
-
0037861923
-
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
-
White W.B., Carr A.A., Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. 92:2003b;38-42
-
(2003)
Am. J. Cardiol.
, vol.92
, pp. 38-42
-
-
White, W.B.1
Carr, A.A.2
Krause, S.3
Jordan, R.4
Roniker, B.5
Oigman, W.6
|